Zollinger-Ellison syndrome (ZES) is a rare disease. Its management concerns symptoms related to the gastric acid overproduction that characterizes the syndrome and to the gastrin-producing tumor(s) usually located in the duodenal wall and/or the endocrine pancreas. Acid hypersecretion is now controlled by the use of powerful antisecretory agents. Management of the malignant process(es) has become the primary goal of modern strategy: it aims first at curing the disease and second at prolonging patient survival by prevention of hepatic metastasis. In patients with the sporadic form of the disease and without liver metastases, it is currently possible to localize and to surgically remove the endocrine tumor(s). This progress has been made feasible by refinements in modern medical imaging. At present, however, disease cure, even in the most favorable conditions, is not be greater than 30 to 50 percent at five years. In patients with ZES integrated in the context of multiple endocrine neoplasia type I, disease cure rate is extremely low, although occasional patient survival can be as good or even better than in the sporadic group. Disseminated malignancy (liver and/or extra-abdominal lymph nodes or bone localization) remains the principal determinant of early death. Surgical treatment is usually precluded in such cases. Liver transplantation has not been successful in these patients.
It soon appeared, however, that gastrinoma management was more complex than initially anticipated. Understanding of the oncologic process remains incomplete. We are not able to explain why some patients, even with liver metastases, undergo a relatively indolent course, or why metastases to lymph nodes on the one hand and to liver on the other hand, although both indicate malignancy, behave differently, only the latter influencing patient survival.
Indications and contraindications of surgery remained, therefore, highly controversial with firm opponents to surgery arguing that, except in very rare and selected cases [12] , there is a minute chance of a long-term satisfactory cure rate (15 percent according to Hirschowitz 's experience and a review of 15 series by Ellison et al. [13] ). On the contrary, many other groups, including the NIH group at Bethesda and our group in Paris, on the basis of the results of earlier experience, advocated explorative laparotomy in the sporadic form of the disease, except in patients with diffuse liver metastases. The NIH group extended this indication even to ZES patients with multiple endocrine neoplasia type I (MEN-1) [3] , provided an imageable tumor was found. We did not adopt this recommendation, as it was not supported by the results of a long-term follow-up of 45 consecutive patients followed in our institution [14, 15] .
Several recent reports on large series of patients have provided very significant information on two relevant factors: 1) ZES patient survival depends essentially on the presence of distant metastases, which, in turn, seems to depend upon the size and the localization of the primary tumor(s), and 2) disease cure-rate by surgery seems to depend upon the clinical condition (with or without MEN-1) and the possibility of removal of the primary tumor as completely as possible [3] . Recent refinements in medical imaging, bothpre-and intra-operatively, have been of great help to the surgeons. Further assessment of new technology is in progress, namely of intra-operative isotopic detection of the tumors using hand-held probes after I 1I n-Pentetreotide administration. Additive information has been also sought for from the use of biological markers aiming at predicting the biological behavior of the tumor.
Tumor proliferation markers such as proliferating cell nuclear antigen (PCNA) or quantitative DNA analysis using flow cytometry have been performed by several groups on endocrine tumors of the pancreas [16, 17] . Results of PCNA studies indicated that the lower the frequency of cells expressing the antigen within the tumor, the better was the survival [16] . Similarly, a close statistical correlation has been found between the degree of quantitative abnormalities of primary tumor DNA content and tumor spread [17] . The prognostic significance of the CD44 expression in gastrinoma (i.e., restricted tumor spread, usually to lymph-nodes in CD44-positive tumors) in contrast to the CD44-negative tumors, which are more prone to be locally invasive and/or metastasize to the liver [18] has not been confirmed in a group of 10 gastrinoma patients studied by our group (unpublished observations).
DETERMINANTS OF SURVIVAL IN PATIENTS WITH ZOLLINGER-ELLISON SYNDROME.
Liver metastases are present in about 25 percent of ZES patients [1, 2, 3, 13] .
Although individual patients with long-term survival have been observed in most centers caring for ZES patients, it is commonly observed that less than half of the ZES patients with liver metastases survive beyond five years [1, 2, 13, 19, 20] and less than 30 percent beyond 10 years [20] : the median survival at five years ranges from 17 to 53 percent. In contradistinction to liver metastases, the presence of lymph-node metastases, although as prevalent as liver metastases, does not seem to influence survival rate in ZES patients [1, 9, 20, 21] .
It is not clearly established that chemotherapy or other medical therapies increase survival since no comparisons of randomized treatments against placebo have been performed.
In sporadic ZES cases, the determinants affecting the development of hepatic metastases clearly appear to be the size and the location of the primary tumor [13, 20] . Patients presenting with hepatic metastases have larger primary tumors than patients without metastases, while no such relationship exists between primary tumor size and development of lymph-nodes metastases [20] . In the NIH series, indeed, in patients harboring tumor(s) of more than 3 cm diameter, usually located in the pancreas, liver metastases were noted in 61 percent of the cases [20] . Pancreatic tumors, usually large, are associated with liver metastases in 52 percent of sporadic cases; seven percent of these patients have both lymph node and liver involvement [20] . In contrast, duodenal tumors, which usually are of small size, are associated with liver metastases in only five percent of the cases, while they are associated with regional lymph node involvement in the same proportion as in case of pancreatic primary(ies) [20] .
These very important findings seem to be in keeping with the anatomical stratification proposed by Howard et al. [22] , which sharply separates the patients having primary tumors located on the right of the superior mesenteric artery, within the so-called gastrinoma triangle, from those patients having pancreatic tumors to the left of the superior mesenteric artery; in the latter group, liver metastases were much more prevalent (56 percent of patients) and the actuarial survival was poor (less than 10 percent at 10 years).
EXPLORATIVE LAPAROTOMY IN PATIENTS WITHOUT DISTANT METASTASES An oncological approach in the surgical management of tumors in patients with sporadic ZES has been vigorously suggested by several groups [1, 4, 23] , and discussed by others [24] . Most 16.8) , liver metastases developed in only 3.1 percent of the patients who underwent surgery as compared to 23 percent of the patients who did not undergo surgery (p < .003). Disease-specific actuarial survival was 100 percent at 15 years in the group in whom surgery was performed. In contrast, two deaths related to progression of. liver metastases, were noted in the nonoperated group. Although the difference in survival between these two groups of patients did not reach statistical significance, these findings are of the utmost importance, suggesting a high benefit in terms of prevention of hepatic metastases. This approach clearly deserves further testing by prospective evaluation.
DETERMINANTS OF DISEASE-CURE BY SURGERY In contrast to sporadic ZES patients, in whom it appears reasonable to attempt tumor eradication in the absence of non-resectable liver involvement, in patients with MEN-1-ZES exploratory laparotomy is seldom indicated (other than for symptomatic associatedendocrine secretion), as the chance of a definite cure by surgery is very low. Parathyroid surgery is often indicated and should take place before any form of abdominal surgery.
Indeed, in this clinical setting, anatomical distribution and tumor morphology are different from sporadic cases, being usually multiple, disseminated throughout the duodenopancreatic area, of small size, and perhaps associated with endocrine cell hyperplasia. Several types of pancreatic endocrine cell proliferation may coexist in MEN-1 patients. One of the most puzzling situations has been the association of gastrin and insulin overproduction within pancreatic tumors as noted in 13 percent of cases of ZES with MEN-1 in our experience. Figure 1 represents the basic flow chart adopted at the Bichat-Claude Bernard Hospital for the detection of MEN-1. The oral calcium tolerance test has been evaluated prospectively in our institution in 28 patients with normal fasting total plasma calcium to detect primary hyperparathyroidism [25] .
Fasting total and ionized calcium and PTH 1-84 levels were measured, and nephrogenous cAMP was calculated during a two-hour baseline period and during a two-hour period after the oral administration of 1 g inorganic calcium. The diagnosis of normocalcemic primary hyperparathyroidism was established when, during the oral calcium tolerance test, plasma ionized calcium concentration increased to supranormal values and only a minimal reduction in plasma PTH concentration and nephrogenous cAMP excretion was observed. Among the patients with normal fasting total calcium levels, the test established the diagnosis of normocalcemic primary hyperparathyroidism in five (20 percent) and of hypercalcemic primary hyperparathyroidism in three patients. In nine percent of the patients with apparently sporadic type of the ZES (no other endocrinopathy and no familial disease), normocalcemic primary hyperparathyroidism was the sole manifestation of MEN-1. Thus, in this prospective study, a diagnosis of normocalcemic primary hyperparathyroidism was established in four out of 23 ZES patients with normal basal serum calcium levels [25] .
The management strategy in patients with ZIS-MEN-I that has been adopted at the Bichat Hospital derives from the experience gained with the aggressive surgical approach that was applied to these patients from 1959 to 1981 [14, 15] . As illustrated in Figure 2 , 36 patients underwent some form of gastrinoma surgery. After surgery 22 patients were judged tumor-free and seven had residual tumor. On subsequent follow-up, only one remained, apparently cured after 96 months; in all other cases, persisting clinical or biologic abnormalities have been noted, and overt tumor(s) recurrence has been documented. [20] with the permission of the Editor.
I
Actuarial survival, at 15 years, in the ZES-MEN-1 patients followed in our institution was 63 percent, thus slightly better than in sporadic cases (45 percent) [26] . In addition, when the mortalities for both categories of ZES were compared (Table 1) , a trend in favor of the ZES-MEN I group was noticeable in terms of death related to liver metastatic progression. When deaths unrelated to liver metastases were excluded from our evaluation, survival rate after a median follow-up of 95 months (range: 17 to 278) for the whole population was 78 percent, a figure close to the one reported by Weber et al. [20] . It is possible, as suggested by the prospective long-term study of the large group of patients studied at the NIH by Weber et al. [20] , that there are two forns of ZES with strikingly different clinical outcomes. A comparison of the main clinical characteristics of these two groups of patients is illustrated in Table 2 .
Will such a posteriori stratification and its consequent ZES management-guidelines benefit the patients not only with regard to survival but also for disease cure? According to results reviewed by Fraker and Norton [23] , and our own experience up to 1985 [1] , the chance of a definite cure by tumor removal in those patients without distant metastases and without MEN-I approximated 18 to 20 percent in patients with pancreatic gastrinomas, and up to 40 to 65 percent in those patients with extra-pancreatic gastrinomas (i.e., tumors located in the duodenal or the gastric wall, isolated lymph node metastasis) [1] . Altogether in the NIH experience, however, the cure rate at five years appears to be about 30 percent, although this rate amounted to 58 percent at three months [27] . In the group [30] .
of 42 patients, however, who were found to be disease-free after surgery as defined by no evidence of tumor on imaging studies, normal fasting gastrin level, and negative provocative test, the proportion of disease-free patients amounted to 62 percent at five years and a little less than 50 percent at nine years [27] . It is essential to emphasize that comparison of the survival curves in patients who underwent surgical exploration for possible complete tumor resection at the NIH [10, 20] showed no significant difference whether the patients were rendered disease-free or not.
PRESENT STRATEGY FOR ZES MANAGEMENT AT THE BICHAT-CLAUDE BERNARD INSTITUTION
The policy that has been presently adopted at the Bichat-Claude Bernard Hospital has been outlined in Table 3 . It emphasizes the necessity before considering surgery in ZES patients: 1) to exclude the presence of MEN-1; 2) to eliminate the presence of distant metastatic spread; and 3) to make the strongest efforts at precise localization of the primary tumor(s). Modern medical imaging (i.e., endoscopic ultrasonography and somatostatin-receptor scintigraphy using IIlIn-Pentetreotide) are of the greatest help as illustrated in Tables 4 and 5 [29, 30, 311 . As shown in Tables 5 and 6 , somatostatin-recep- From: *Gibnl et al. [31] : tcalculation from available data in the abstract; **Cadiot et al. [32] ; *** Bonnaud et al. [33] . tor scintigraphy is slightly less sensitive than ultrasonography in detection of primaries in the duodeno-pancreatic area. However both techniques are, in our experience, complementary since each one can reveal tumor masses undetected by the other [29, 32] . Concerning the detection of extrapancreatic gastrinoma, for instance, the combination of ultrasonography and somatostatin-receptor scintigraphy yielded positive results in 90 percent of our patients [32] . In addition to tumor localization, somatostatin-receptor scintigraphy has been evaluated at both the NIH and our institution in terms of patient management guidance, as shown in Table 5 [3, 34] . The experience of two surgical groups indicates that extensive resection including major hepatic resection is feasible, safe and can be repeated. Clinical outcome after hepatic resection, compared to the natural history of these tumors, demonstrates that this procedure is valuable in terms of symptoms palliation and prolongation of survival, provided a thorough selection of candidates for surgery and a significant resection of tumor deposits can be performed [34] . Partial hepatic resection can be combined with tumor debulking to facilitate the synergistic effect of various other forms of treatment such as chemotherapy, serial arterial embolization or repeated transient hepatic ischemia.
Vascular occlusive therapy of pancreatic endocrine tumors metastatic to the liver has been updated and discussed recently by Arcenas et al. [35] . Although it is beneficial in patients with liver metastasis originating from gut carcinoid tumors, efficacy in gastrinoma patients has not yet been sufficiently evaluated [35, 36] .
Considerable hope had been placed on systemic chemotherapy. Early experience with regimens using a combination of streptozotocin (STZ) and 5 fluoro-uracil (5FU) yielded the best response rates [37] . The median remission duration in the whole group of patients was only 17 months, but there was a trend toward longer survival (26 months) in the STZ-5FU group versus those receiving STZ alone (16.5 months) . Valid interpretation of these results, however, remained uncertain in ZES because of the small number of ZES patients concerned (eight out of 84 endocrine pancreatic tumors) and because judgement criteria were essentially biological. Recent prospective studies [19, 38] [39] and to be modest and inconstant [39, 40] .
The advent of liver transplantation raises a challenging therapeutic option for liver metastases from endocrine gut tumors that are recognized as having a slow evolution [41] . Makowka et al. from Starzl's group [42] reported results from five such patients (one with gastrinoma). Their results appeared encouraging for two glucagonoma patients who remained disease-free 23 and 41 months later. The only gastrinoma patient, who was initially free of extrahepatic metastases, died eight months later from multiple lung and bone metastases.
A large French experience with liver transplantation for neuro-endocrine liver metastasis extending from 1989 to 1994 has been recently analyzed and published in an abstract form [43] : the main results are shown in Table 6 . As can be noted, with the exception of gut carcinoids, results of liver transplantation are not encouraging for the pancreatic endocrine tumors inclusive of gastrinomas. In addition, a real problem for such a tremendous decision is when to perform liver transplantation? In a study of 35 patients with endocrine-type liver metastases including 20 cases of ZES, we looked for factors specific to endocrine-type liver metastases that could be used as major prognostic indicators of death and, thus, could be of help in selecting the appropriate time for liver transplantation [44] . Among the various elements assessed over a patient's observation period of 35 months (median duration; range: five to 136 months), only rapid expansion of metastatic volume of the liver (more than 25 percent within six months) seemed to be a major prognostic factor leading to consideration of liver transplantation in patients below 55 to 60 years without bone and lung metastases and non-responding to other forms of therapy.
There is insufficient experience with interferon in gastrinoma patients with liver metastases; interesting results obtained in carcinoid tumors suggest interferon could be worth testing in ZES patients, possibly in association with octreotide [45] . CONCLUSIONS The role of medical treatment is essential in gastrinoma management for a large group of patients since:
1. Unresectable hepatic metastases are present in about 25 percent of patients with ZES.
2. Surgery is usually unable to achieve disease-cure in MEN-i -ZES cases (25 percent of patients with ZES). 3 . Recurrence rate is 50 percent at nine years without affecting survival, even in benign forms of sporadic ZES, according to the NIH stratification.
Results of the long-term study at the NIH suggest, however, that in sporadic forms of the disease, surgery could play a major role to prevent liver metastasis development; this suggestion, however, requires further testing. Surgery, in any case, must be safe, performed by experienced surgical-medical teams. and restricted to simple procedures.
The time has probably come to initiate multicenter, multinational studies to test: 1. The NIH-proposed stratification between benign and malignant forms of ZES through retrospective and prospective, randomized clinical experiences.
2. The role of surgery in MEN-1-ZES patients.
